We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Repros Therapeutics' (RPRX) Proellex Positive in Phase II
Read MoreHide Full Article
Repros Therapeutics Inc. (RPRX - Free Report) announced positive results from a phase II study, evaluating its pipeline candidate, Proellex, for the treatment of premenopausal women with moderate to severe endometriosis.
The double-blinded phase II study showed encouraging outcomes with 70% of the patients treated with oral Proellex experiencing relief from menstrual pain and a reduction in the use of pain medication compared to the placebo arm. Menstrual pain, as measured by the BBSS (Biberoglu and Behrman Symptom Score) score, in patients treated with Proellex decreased significantly, compared to those treated with placebo. Pill count of subjects treated with Proellex showed a reduction of 56% compared 30% in the placebo arm. Proellex was found to be well tolerated in the study.
The drug was tested on 60 subjects with a mean age group of 30, comprising 13 patients from Argentina and 47 from the U.S.
Currently, there are no FDA-approved oral drugs for the long-term treatment of uterine fibroids or endometriosis.
If successfully developed and commercialized, Proellex could prove to be a breakthrough treatment, catering to a huge population of women. According to the Endometriosis Association, the disease is estimated to affect 6.3 million women in the U.S. and Canada, and millions more in the rest of the world.
Repros is planning to have a discussion with the FDA for the late-stage development of Proellex and phase III studies to treat women struggling with painful menstruation.
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand.Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Repros Therapeutics' (RPRX) Proellex Positive in Phase II
Repros Therapeutics Inc. (RPRX - Free Report) announced positive results from a phase II study, evaluating its pipeline candidate, Proellex, for the treatment of premenopausal women with moderate to severe endometriosis.
The double-blinded phase II study showed encouraging outcomes with 70% of the patients treated with oral Proellex experiencing relief from menstrual pain and a reduction in the use of pain medication compared to the placebo arm. Menstrual pain, as measured by the BBSS (Biberoglu and Behrman Symptom Score) score, in patients treated with Proellex decreased significantly, compared to those treated with placebo. Pill count of subjects treated with Proellex showed a reduction of 56% compared 30% in the placebo arm. Proellex was found to be well tolerated in the study.
The drug was tested on 60 subjects with a mean age group of 30, comprising 13 patients from Argentina and 47 from the U.S.
Currently, there are no FDA-approved oral drugs for the long-term treatment of uterine fibroids or endometriosis.
If successfully developed and commercialized, Proellex could prove to be a breakthrough treatment, catering to a huge population of women. According to the Endometriosis Association, the disease is estimated to affect 6.3 million women in the U.S. and Canada, and millions more in the rest of the world.
Repros is planning to have a discussion with the FDA for the late-stage development of Proellex and phase III studies to treat women struggling with painful menstruation.
REPROS THERAPEU Price
REPROS THERAPEU Price | REPROS THERAPEU Quote
Zacks Rank & Other Key Picks
Repros Therapeutics currently carries a Zacks Rank #2 (Buy). Other favorably placed stocks in the medical genetics sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and Cambrex Corporation . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>